Data suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
The inclusion of pharmacoeconomic endpoints in Phase III clinical trials presents a stronger package in support of a US product launch.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial